The SRAP feasibility study led by nano4U and concluded in late 2018 shows some nervousness in the pharmaceutical industry regarding the levels of product recalls and the ability to truly authenticate products in the supply chain. The EU Falsified Medicines Directive has introduced a complex supply chain tracking system for prescription medicines in Europe. However, this does not authenticate the product but only checks its secondary packaging (carton). Authentication of the product itself (as opposed to its packaging code) normally requires breaking open of the primary packaging making the medication unusable or destroying it. SRAP technology offers a solution to this problem by allowing authentication of the product itself and complete protection against tampering – in a serialisation-compatible manner if needed – without removing the product from its packaging, removing it to a lab, adding anything to the tablet recipe, and with or without a database. This is seen as a breakthrough technology that can be applied in the pharmaceutical industry to substantially reduce the risks associated with recalls (financial and other), as well as fundamentally improving the safety of patients.
This project received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 808887.